Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Increased by Black Creek Investment Management Inc.

Black Creek Investment Management Inc. increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 60.9% in the 2nd quarter, HoldingsChannel reports. The firm owned 2,338,970 shares of the medical equipment provider’s stock after acquiring an additional 885,524 shares during the quarter. Hologic makes up approximately 6.5% of Black Creek Investment Management Inc.’s holdings, making the stock its 9th largest holding. Black Creek Investment Management Inc.’s holdings in Hologic were worth $173,669,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Innealta Capital LLC purchased a new stake in Hologic in the 2nd quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new stake in Hologic during the first quarter valued at $37,000. Mather Group LLC. purchased a new position in Hologic in the first quarter valued at $48,000. Massmutual Trust Co. FSB ADV raised its position in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 137 shares during the period. Finally, Toth Financial Advisory Corp boosted its stake in shares of Hologic by 81.1% during the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 347 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of analyst reports. JPMorgan Chase & Co. upped their price target on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Evercore ISI increased their target price on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research note on Friday, August 16th. StockNews.com raised shares of Hologic from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th. Finally, Stephens reissued an “overweight” rating and set a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Hologic Stock Performance

HOLX opened at $81.15 on Monday. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67. The firm has a market capitalization of $18.85 billion, a PE ratio of 41.40, a PEG ratio of 2.53 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The firm’s 50-day moving average price is $80.20 and its 200 day moving average price is $76.86.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the firm posted $0.93 EPS. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. As a group, sell-side analysts expect that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 in the last three months. 1.75% of the stock is owned by corporate insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.